Impact of Influenza and Pneumococcal Polysaccharide Vaccination on Economic Burden from Acute Exacerbations of Chronic Obstructive Pulmonary Disease — Hebei Province, China, November 2018 to November 2020

WHAT IS ALREADY KNOWN ON THIS TOPIC? Chronic obstructive pulmonary disease (COPD) exacerbations increase household economic burden, but there is limited evidence from prospective cohort studies in China about the impact of vaccination on economic burden. WHAT IS ADDED BY THIS REPORT? This study demo...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Yan, Zhang, Pingshu, An, Zhijie, Ma, Ying, Wang, Yamin, Wang, Liye, Liu, Yunqiu, Yuan, Xiaodong, Li, Keli, Yin, Zundong, Wang, Huaqing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Editorial Office of CCDCW, Chinese Center for Disease Control and Prevention 2023
Materias:
Preplanned Studies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10236643/
https://www.ncbi.nlm.nih.gov/pubmed/37274769
http://dx.doi.org/10.46234/ccdcw2023.086
Descripción
Sumario:WHAT IS ALREADY KNOWN ON THIS TOPIC? Chronic obstructive pulmonary disease (COPD) exacerbations increase household economic burden, but there is limited evidence from prospective cohort studies in China about the impact of vaccination on economic burden. WHAT IS ADDED BY THIS REPORT? This study demonstrated the economic burden of COPD exacerbations, pneumonia, and hospitalization in COPD patients in China is substantial. Influenza vaccine and 23-valent pneumococcal polysaccharide vaccine (PPSV23), separately or together, were significantly associated with decreased economic burden. WHAT ARE THE IMPLICATIONS FOR PUBLIC HEALTH PRACTICE? Our study supports evidence on recommendations that COPD patients in China are offered both influenza vaccine and PPSV23.

Ejemplares similares